Pharmacokinetics and pharmacodynamics of nab ‐paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent‐based paclitaxel
Author:
Affiliation:
1. Celgene CorporationSummitNJUSA
Funder
Celgene Corporation
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.304
Reference31 articles.
1. Abraxane [package insert]. Summit NJ: Celgene Corporation;2013.
2. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.
3. Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
4. Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
5. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Cited by 95 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Innovative strategies for effective paclitaxel delivery: Recent developments and prospects;Journal of Oncology Pharmacy Practice;2024-01-10
2. Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer;npj Precision Oncology;2023-12-08
3. Clinical decision support for chemotherapy‐induced neutropenia using a hybrid pharmacodynamic/machine learning model;CPT: Pharmacometrics & Systems Pharmacology;2023-08-10
4. Phase I study of cisplatin and nanoparticle albumin‐bound‐paclitaxel combined with concurrent radiotherapy in locally advanced esophageal squamous cell carcinoma;Cancer Medicine;2023-06-19
5. Triple-Negative Breast Cancer: Basic Biology and Immuno-Oncolytic Viruses;Cancers;2023-04-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3